National and Kapodistrian University of Athens
Μελέτη μορίων που παίζουν σημαντικό ρόλο στην ανάπτυξη των πρωτόζωων Leishmania και Trypanosoma
Abstract
dc:descriptionLeishmania spp., Trypanosoma brucei and Trypanosoma cruzi are trypanosomatid protozoan parasites that cause leishmaniasis, Human African Trypanosomiasis (HAT) and American Trypanosomiasis (Chagas Disease) respectively. These neglected tropical diseases cause considerable morbidity and mortality worldwide. Currently there are no effective human vaccines for their prevention, whereas chemotherapy is often ineffective or toxic. For this reason, the discovery of new antiparasitic agents is of prime importance. It is imperative that the rational design of new medicines focuses on both the identification of candidate parasite targets that their inhibition affect parasite viability or virulence and the design of such inhibitors based on Structure-Activity Relationship (SAR) studies. Overall this strategy is anticipated to lead to an effective rational drug design. The search for drug targets requires a multidisciplinary approach. The completion of the genome project of many trypanosomatid species gives a vast amount of new information that can be exploited for the identification of putative drug candidates with a prediction of “druggability” based on their divergence from the mammalian host proteins. This thesis focuses on important parasite proteins that could constitute putative molecular drug targets for the treatment of leishmaniasis and HAT, because the inhibition of their activity is expected to modulate virulence and cell-cycle progression. Special emphasis is given on Glycogen Synthase Kinase 3 (GSK-3) and the cdc2-related kinase 3 (CRK3). A number of indrirubin analogues (a natural bis-indole present in mollusks and plants), that target these kinases by binding in the ATP-binding pocket, have potent anti-parasitic and parasite-specific activity. Their mode of action suggests important differences in the active sites between these Leishmania and T. brucei kinases, but also between the parasitic kinases and their human homologues. At the same time, these inhibitors were tested for their activity against Τ. cruzi parasites in vitro and in vivo. Finally, one inhibitor was found to be promising against Chagas disease in Balb/C mice while two GSK-3 inhibitors were found to have promising activity in both the acute and chronic phase of visceral leismaniasis in the Balb/C experimental model. The above results could contribute to the search of potent drugs that could be exploited in a combined treatment schema for the above diseases or/and enhance the study of the in vivo mechanisms of action of the GSK-3 inhibitors. Overall, the results described above contribute to the concentrated international efforts towards the development of targeted drugs focusing on the kinome for the treatment of leishmaniasis, HAT and Chagas disease.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Efstathiou, Antonia
- Ευσταθίου, Αντωνία
Subjects
dc:subject × 12Rights
dc:rights- Statement dc:rights
-
- BY
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44239